ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II cl…
Biotechnology
US, Winston-Salem [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about ProKidney Corp.'s gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2023 | -2.4100 | -0.607 | 0 | 0 | -148 | -35 | -143 | 0 | -156 | 0 | 70 | 0 |
| 2024 | -0.5700 | -0.500 | 0 | 0 | -35 | -30 | -148 | 0 | -151 | 0 | 41 | 0 |
| 2025 | - | -0.526 | - | 0 | - | -30 | - | 0 | - | 0 | - | 0 |
| 2026 | - | -0.680 | - | 0 | - | 2.F3X/td> | - | 2.F31/td> | - | 2.F31 | - | 2.F31 |
| 2027 | - | -0.840 | - | 0 | - | 1.F4X/td> | - | 1.F41/td> | - | 1.F41 | - | 1.F41 |
| 2028 | - | -0.320 | - | 0 | - | 0.F5X/td> | - | 0.F51/td> | - | 0.F51 | - | 0.F51 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
JP Morgan Chase
1Y Ago:
Equal-Weight
Prev. Grade
n/a
Dec. 1, 2024
Equal-Weight
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the gradePrice Target Consensus
-219.863% $3.21 · MISS
Nov. 6, 2024Price Then
$1.62
Price Target
$4.67
Price Now
$1.46